

LIFELINE THERAPEUTICS, INC.

Form 8-K

April 06, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 5, 2006**

**Lifeline Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Colorado**

**000-30489**

**84-1097796**

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

6400 South Fiddler s Green Circle, Suite 1970, Englewood, CO 80111

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code: (720) 488-1711

6400 South Fiddler s Green Circle, Suite 1750, Englewood, CO 80111

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01 Regulation FD Disclosure

On March 29, 2006, the Company filed on Form 8-K a Regulation FD Disclosure. The exhibit attached contained two pages of financial information. The graphical information on those pages did not display correctly, making the information difficult to read.

The pages, in a different format, are attached.

It remains the Company's policy that it will not provide guidance as to future performance of the Company or of its operating results.

ITEM 9.01. Exhibits

99.1 Presentation dated March 06

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: April 5, 2006

LIFELINE THERAPEUTICS, INC.

By: /s/ Gerald J. Houston  
Gerald J. Houston  
Chief Financial Officer

**Exhibit**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Presentation dated March 06